EU orphan designations
Every medicine the European Commission has designated as an orphan medicine for a rare disease, on the EMA's recommendation, with its current status.
Matching designations
3 matches| Substance | Intended use | Status | Designated |
|---|---|---|---|
| urokinase, catalytic domain, fused with a single-chain antibody against von Willebrand factor EU/3/24/2946 3 clinical trials → |
Treatment of thrombotic thrombocytopenic purpura | Active (positive) | 25 Jul 2024 |
| adenoviral vector of serotype 5 modified to contain a chimeric sequence consisting of a minimal urokinase-type plasminogen activator receptor promoter preceded… EU/3/17/1917 |
Treatment of pancreatic cancer | Active (positive) | 16 Oct 2017 |
| single-chain urokinase plasminogen activator EU/3/14/1383 |
Treatment of pleural empyema | Active (positive) | 16 Dec 2014 |
How this page is built
Every row is copied from the EMA's orphan designations data, reproduced with acknowledgement of the source. Each substance links to its official EMA page.
- EMA orphan designations data (JSON report) ↗ active substance, intended use, EU designation number, date of designation, status and the link to each designation page
A daily job downloads the EMA's orphan designations JSON report and lists every designation, newest first. No AI drafting and no editorial pass. See our editorial standards. The the EMA data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.